US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Global Partners LP

42.64

+0.74001.77%

Post-market: 42.640.00000.00%16:18 EST

Volume:33.93K

Turnover:1.44M

Market Cap:1.45B

PE:20.49

High:42.65

Open:42.10

Low:41.68

Close:41.90

52wk High:60.00

52wk Low:39.58

Shares:34.00M

Float Shares:27.67M

Volume Ratio:0.61

T/O Rate:0.12%

Dividend:3.02

Dividend Rate:7.08%

EPS(TTM):2.08

EPS(LYR):2.45

ROE:13.77%

ROA:3.98%

PB:2.39

PE(LYR):17.43

Loading ...

Overview Company News Filings

China's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk

Global GP LLC Reports Acquisition of Global Partners LP Common Shares

Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says

MT Newswires Live

BESUNYEN (00926) Increases Investment in ERX to Maintain 3% Stake, Backing Non-GLP-1 Obesity Therapy Innovation

Youcare Pharmaceutical's Song Gengshen Warns: GLP-1 Weight Loss Drugs May Cause Depression, Dubbed "Emotion-Numbing Medication"

FTC Release: FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs

Global GP LLC Reports Acquisition of Global Partners LP Common Shares

Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025

CSPC PHARMA (01093): GLP-1/GIP Receptor Dual-Targeting Agonist Polypeptide Injection Approved for Clinical Trials in the U.S.

Lepu Biopharma (SEHK:2157): Valuation Check After New GLP-1 CDMO Framework Deal With Lepu Medical

Simply Wall St.

Global GP LLC Reports Acquisition of Global Partners LP Common Shares

SINO BIOPHARM (01177) Receives NMPA and FDA Approval for Clinical Trial of TQF3250, an "Oral Biased GLP-1 Receptor Agonist"

FTC Release: FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs

Burger King Primed for GLP-1 Shift -- Market Talk

Global GP LLC Reports Acquisition of Global Partners LP Common Shares

Are GLP-1s The New Performance-Enhancing Drug For Careers?

ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development

Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

GLP J-REIT Signs Interest Rate Swap Agreements to Stabilize Borrowing Costs

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GLP/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GLP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","market":"US","secType":"STK","nameCN":"Global Partners LP","latestPrice":42.64,"timestamp":1767992400000,"preClose":41.9,"halted":0,"volume":33926,"hourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:18 EST","volume":1613,"amount":68778.43,"timestamp":1767993485776},"delay":0,"floatShares":27674174,"shares":33995563,"eps":2.080802,"marketStatus":"Market Closed","change":0.74,"latestTime":"01-09 16:00:00 EST","open":42.1,"high":42.6532,"low":41.68,"amount":1441086.6839,"amplitude":0.023227,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.080802,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1127966400000,"exchange":"NYSE","adjPreClose":41.9,"dividendRate":0.070826,"preHourTrading":{"tag":"盘前","latestPrice":42.49,"preClose":41.9,"latestTime":"08:40 EST","volume":81,"amount":3479.35014,"timestamp":1767966027683},"postHourTrading":{"tag":"盘后","latestPrice":42.64,"preClose":42.64,"latestTime":"16:18 EST","volume":1613,"amount":68778.43,"timestamp":1767993485776},"volumeRatio":0.6117753119932732,"impliedVol":0.3319,"impliedVolPercentile":0.4143},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GLP\",,,,,undefined,":{"symbol":"GLP","floatShares":27674174,"roa":"3.98%","roe":"13.77%","lyrEps":2.44604,"volumeRatio":0.6117753119932732,"shares":33995563,"dividePrice":3.02,"high":42.6532,"amplitude":0.023227,"preClose":41.9,"low":41.68,"week52Low":39.58,"pbRate":"2.39","psRate":"0.08","week52High":60,"institutionHeld":0.4714,"latestPrice":42.64,"eps":2.080802,"divideRate":0.070826,"volume":33926,"delay":0,"ttmEps":2.080802,"open":42.1,"prevYearClose":41.85,"prevWeekClose":42.26,"prevMonthClose":41.85,"prevQuarterClose":41.85,"fiveDayClose":42.26,"twentyDayClose":43.8,"sixtyDayClose":44.75,"dividendPayoutRate":1.1692368072476331,"dividendFrequency":"Q","dividendGrowthYears":0,"dividendGrowthRate":-0.20278745644599305,"fiveYearAvgDividendRate":0.09217143297642297},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GLP\",params:#limit:5,,,undefined,":[{"date":"2025-11-10","symbol":"GLP","amount":0.755,"announcedDate":"2025-10-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-11-10","defaultRemindTime":1762785000000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-11-14","payableDate":"2025-11-10","currency":"USD","dateTimestamp":1762750800000,"payDate":"2025-11-14"},{"market":"US","date":"2025-11-07","symbol":"GLP","fiscalQuarterEnding":"2025/09","expectedEps":1.09,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"pre","actualEps":0.66},{"date":"2025-08-08","symbol":"GLP","amount":0.75,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-08-08","defaultRemindTime":1754659800000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-08-14","payableDate":"2025-08-08","currency":"USD","dateTimestamp":1754625600000,"payDate":"2025-08-14"},{"market":"US","date":"2025-08-07","symbol":"GLP","fiscalQuarterEnding":"2025/06","expectedEps":0.6,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":0.55},{"date":"2025-05-09","symbol":"GLP","amount":0.745,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-09","defaultRemindTime":1746797400000,"name":"Global Partners Lp","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-15","payableDate":"2025-05-09","currency":"USD","dateTimestamp":1746763200000,"payDate":"2025-05-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GLP\",market:\"US\",,,undefined,":[{"executeDate":"2016-02-08","recordDate":"2016-02-10","paymentDate":"2016-02-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-05-04","recordDate":"2016-05-06","paymentDate":"2016-05-16","value":0.4625,"currency":"USD"},{"executeDate":"2016-08-04","recordDate":"2016-08-08","paymentDate":"2016-08-12","value":0.4625,"currency":"USD"},{"executeDate":"2016-11-04","recordDate":"2016-11-08","paymentDate":"2016-11-14","value":0.4625,"currency":"USD"},{"executeDate":"2017-02-07","recordDate":"2017-02-09","paymentDate":"2017-02-14","value":0.4625,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GLP\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":2,"updateTime":1741064400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GLP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GLP","date":"2026-01-09","current":20.492099,"percent":0.824238,"low":2.771386,"twenty":4.440923,"median":11.163158,"eighty":17.676428,"high":29.34912,"avg":11.806759,"sd":6.388659,"marketCap":1417302654},"quantilePoints":[{"date":"2021-01-15","current":6.216526,"twenty":6.149862,"median":7.785585,"eighty":11.084422,"marketCap":595350479},{"date":"2021-01-22","current":6.705707,"twenty":6.149862,"median":7.780094,"eighty":11.074992,"marketCap":642198851},{"date":"2021-01-29","current":7.180605,"twenty":6.149862,"median":7.776202,"eighty":11.068208,"marketCap":687679388},{"date":"2021-02-05","current":7.284155,"twenty":6.149862,"median":7.768418,"eighty":11.06411,"marketCap":697596196},{"date":"2021-02-12","current":6.934229,"twenty":6.163202,"median":7.760634,"eighty":11.053134,"marketCap":664084222},{"date":"2021-02-19","current":7.112763,"twenty":6.167321,"median":7.75285,"eighty":11.04396,"marketCap":681182168},{"date":"2021-02-26","current":7.202029,"twenty":6.167844,"median":7.741174,"eighty":11.038761,"marketCap":689731141},{"date":"2021-03-05","current":6.896217,"twenty":6.167844,"median":7.718575,"eighty":11.032407,"marketCap":695214499},{"date":"2021-03-12","current":7.842623,"twenty":6.167844,"median":7.698362,"eighty":11.017031,"marketCap":790622686},{"date":"2021-03-19","current":7.720506,"twenty":6.167844,"median":7.718575,"eighty":11.007626,"marketCap":778311953},{"date":"2021-03-26","current":7.411822,"twenty":6.167844,"median":7.69367,"eighty":11.00501,"marketCap":747193153},{"date":"2021-04-01","current":7.320234,"twenty":6.167844,"median":7.686686,"eighty":10.988222,"marketCap":737960103},{"date":"2021-04-09","current":7.3779,"twenty":6.167844,"median":7.67501,"eighty":10.954813,"marketCap":743773505},{"date":"2021-04-16","current":7.510194,"twenty":6.168749,"median":7.659442,"eighty":10.940212,"marketCap":757110133},{"date":"2021-04-23","current":7.364332,"twenty":6.170107,"median":7.594997,"eighty":10.930856,"marketCap":742405645},{"date":"2021-04-30","current":8.185229,"twenty":6.171613,"median":7.641929,"eighty":10.912383,"marketCap":825161134},{"date":"2021-05-07","current":9.181725,"twenty":6.178654,"median":7.67501,"eighty":10.905455,"marketCap":849502414},{"date":"2021-05-14","current":8.749253,"twenty":6.185826,"median":7.686686,"eighty":10.905455,"marketCap":809489619},{"date":"2021-05-21","current":9.203903,"twenty":6.185826,"median":7.690578,"eighty":10.897433,"marketCap":851554353},{"date":"2021-05-28","current":9.407203,"twenty":6.185826,"median":7.712361,"eighty":10.877257,"marketCap":870363786},{"date":"2021-06-04","current":9.706607,"twenty":6.189262,"median":7.720506,"eighty":10.864653,"marketCap":898064952},{"date":"2021-06-11","current":10.061456,"twenty":6.203126,"median":7.741174,"eighty":10.858681,"marketCap":930895963},{"date":"2021-06-18","current":9.603109,"twenty":6.203644,"median":7.748958,"eighty":10.836624,"marketCap":888489240},{"date":"2021-06-25","current":9.680732,"twenty":6.203808,"median":7.760634,"eighty":10.817799,"marketCap":895671024},{"date":"2021-07-02","current":9.658554,"twenty":6.203808,"median":7.768418,"eighty":10.809851,"marketCap":893619086},{"date":"2021-07-09","current":9.31849,"twenty":6.203808,"median":7.778148,"eighty":10.796921,"marketCap":862156033},{"date":"2021-07-16","current":8.963641,"twenty":6.213362,"median":7.780094,"eighty":10.785892,"marketCap":829325022},{"date":"2021-07-23","current":9.495915,"twenty":6.213362,"median":7.785616,"eighty":10.763835,"marketCap":878571539},{"date":"2021-07-30","current":9.909906,"twenty":6.216526,"median":7.795662,"eighty":10.752807,"marketCap":916874385},{"date":"2021-08-06","current":29.34912,"twenty":6.22179,"median":7.817068,"eighty":10.752807,"marketCap":823536295},{"date":"2021-08-13","current":26.023372,"twenty":6.22179,"median":7.822906,"eighty":10.813084,"marketCap":730215805},{"date":"2021-08-20","current":24.554702,"twenty":6.22179,"median":7.83069,"eighty":10.865043,"marketCap":689004931},{"date":"2021-08-27","current":24.530426,"twenty":6.22179,"median":7.834582,"eighty":10.905455,"marketCap":688323760},{"date":"2021-09-03","current":25.100901,"twenty":6.22179,"median":7.842494,"eighty":10.964493,"marketCap":704331289},{"date":"2021-09-10","current":24.275533,"twenty":6.228856,"median":7.848204,"eighty":11.013201,"marketCap":681171460},{"date":"2021-09-17","current":25.198003,"twenty":6.230622,"median":7.85015,"eighty":11.053134,"marketCap":707055975},{"date":"2021-09-24","current":24.894559,"twenty":6.230772,"median":7.876969,"eighty":11.084422,"marketCap":698541332},{"date":"2021-10-01","current":26.047647,"twenty":6.233421,"median":7.883329,"eighty":11.141011,"marketCap":730896976},{"date":"2021-10-08","current":26.897291,"twenty":6.234318,"median":7.892962,"eighty":11.19642,"marketCap":754737977},{"date":"2021-10-15","current":26.836602,"twenty":6.236185,"median":7.896854,"eighty":11.246674,"marketCap":753035049},{"date":"2021-10-22","current":28.632991,"twenty":6.237348,"median":7.914368,"eighty":11.269162,"marketCap":803441737},{"date":"2021-10-29","current":28.329547,"twenty":6.237865,"median":7.935774,"eighty":11.303569,"marketCap":794927093},{"date":"2021-11-05","current":18.151279,"twenty":6.239408,"median":7.94745,"eighty":11.328048,"marketCap":776838422},{"date":"2021-11-12","current":18.191189,"twenty":6.239772,"median":7.988112,"eighty":11.346522,"marketCap":778546510},{"date":"2021-11-19","current":18.773882,"twenty":6.239772,"median":8.014118,"eighty":11.360961,"marketCap":803484595},{"date":"2021-11-26","current":18.694061,"twenty":6.239772,"median":8.035981,"eighty":11.378852,"marketCap":800068419},{"date":"2021-12-03","current":18.103386,"twenty":6.239772,"median":8.105729,"eighty":11.403489,"marketCap":774788716},{"date":"2021-12-10","current":18.430652,"twenty":6.240495,"median":8.179783,"eighty":11.427136,"marketCap":788795038},{"date":"2021-12-17","current":18.550383,"twenty":6.243048,"median":8.213544,"eighty":11.470285,"marketCap":793919302},{"date":"2021-12-23","current":17.991637,"twenty":6.244429,"median":8.252749,"eighty":11.474686,"marketCap":770006070},{"date":"2021-12-31","current":18.749936,"twenty":6.244429,"median":8.284603,"eighty":11.575574,"marketCap":802459742},{"date":"2022-01-07","current":20.051017,"twenty":6.24581,"median":8.291955,"eighty":11.616705,"marketCap":858143411},{"date":"2022-01-14","current":21.152545,"twenty":6.248234,"median":8.320498,"eighty":11.690231,"marketCap":905286640},{"date":"2022-01-21","current":20.146802,"twenty":6.249277,"median":8.363015,"eighty":11.729858,"marketCap":862242822},{"date":"2022-01-28","current":21.392008,"twenty":6.251718,"median":8.365465,"eighty":11.776801,"marketCap":915535168},{"date":"2022-02-04","current":21.85497,"twenty":6.254157,"median":8.433466,"eighty":11.837284,"marketCap":935348988},{"date":"2022-02-11","current":21.559632,"twenty":6.257754,"median":8.47328,"eighty":11.938846,"marketCap":922709137},{"date":"2022-02-18","current":20.945011,"twenty":6.257851,"median":8.48054,"eighty":12.432666,"marketCap":896404582},{"date":"2022-02-25","current":20.529942,"twenty":6.258237,"median":8.487891,"eighty":12.775373,"marketCap":878640467},{"date":"2022-03-04","current":15.348683,"twenty":6.268592,"median":8.571294,"eighty":13.121553,"marketCap":878174885},{"date":"2022-03-11","current":15.504022,"twenty":6.275496,"median":8.601399,"eighty":13.154839,"marketCap":887062603},{"date":"2022-03-18","current":15.940166,"twenty":6.275736,"median":8.649704,"eighty":13.201441,"marketCap":912016580},{"date":"2022-03-25","current":16.890123,"twenty":6.275736,"median":8.669307,"eighty":13.248042,"marketCap":966368393},{"date":"2022-04-01","current":16.214996,"twenty":6.275736,"median":8.68891,"eighty":13.261356,"marketCap":927741004},{"date":"2022-04-08","current":16.752708,"twenty":6.275736,"median":8.726599,"eighty":13.281328,"marketCap":958506181},{"date":"2022-04-14","current":16.573471,"twenty":6.275736,"median":8.736337,"eighty":13.3013,"marketCap":948251122},{"date":"2022-04-22","current":16.011861,"twenty":6.276168,"median":8.777122,"eighty":13.329261,"marketCap":916118604},{"date":"2022-04-29","current":15.743005,"twenty":6.281175,"median":8.797306,"eighty":13.342575,"marketCap":900736015},{"date":"2022-05-06","current":9.804164,"twenty":6.2824,"median":8.848712,"eighty":13.349233,"marketCap":897659497},{"date":"2022-05-13","current":9.69216,"twenty":6.2824,"median":8.9103,"eighty":13.347901,"marketCap":887404438},{"date":"2022-05-20","current":10.270852,"twenty":6.291454,"median":8.930374,"eighty":13.347901,"marketCap":940388910},{"date":"2022-05-27","current":11.163158,"twenty":6.293718,"median":8.972794,"eighty":13.342575,"marketCap":1022087547},{"date":"2022-06-03","current":10.868211,"twenty":6.294536,"median":8.995202,"eighty":13.341244,"marketCap":995082558},{"date":"2022-06-10","current":10.244717,"twenty":6.297672,"median":9.026396,"eighty":13.341244,"marketCap":937996063},{"date":"2022-06-17","current":7.754474,"twenty":6.299555,"median":9.016925,"eighty":13.33725,"marketCap":709991918},{"date":"2022-06-24","current":8.613179,"twenty":6.299659,"median":8.99034,"eighty":13.331924,"marketCap":788614037},{"date":"2022-07-01","current":8.814788,"twenty":6.299659,"median":8.977241,"eighty":13.322603,"marketCap":807073143},{"date":"2022-07-08","current":8.900658,"twenty":6.299659,"median":8.963641,"eighty":13.313284,"marketCap":814935355},{"date":"2022-07-15","current":8.867057,"twenty":6.299659,"median":8.92485,"eighty":13.306626,"marketCap":811858837},{"date":"2022-07-22","current":9.561487,"twenty":6.300172,"median":8.963641,"eighty":13.3013,"marketCap":875440203},{"date":"2022-07-29","current":10.371656,"twenty":6.303369,"median":8.980096,"eighty":13.299969,"marketCap":949618463},{"date":"2022-08-05","current":3.850073,"twenty":6.303369,"median":8.997729,"eighty":13.29198,"marketCap":927520968},{"date":"2022-08-12","current":4.016293,"twenty":6.299659,"median":8.972794,"eighty":13.281328,"marketCap":967565231},{"date":"2022-08-19","current":3.999245,"twenty":6.293991,"median":8.937993,"eighty":13.278687,"marketCap":963458127},{"date":"2022-08-26","current":3.899797,"twenty":6.2824,"median":8.919306,"eighty":13.268103,"marketCap":939500021},{"date":"2022-09-02","current":4.077383,"twenty":6.275736,"median":8.9103,"eighty":13.268014,"marketCap":982282354},{"date":"2022-09-09","current":4.169728,"twenty":6.275496,"median":8.900658,"eighty":13.268014,"marketCap":1004529167},{"date":"2022-09-16","current":4.014873,"twenty":6.257754,"median":8.857885,"eighty":13.261356,"marketCap":967222973},{"date":"2022-09-23","current":3.607134,"twenty":6.247881,"median":8.814788,"eighty":13.254699,"marketCap":868994737},{"date":"2022-09-30","current":3.51621,"twenty":6.240977,"median":8.791187,"eighty":13.254699,"marketCap":847090183},{"date":"2022-10-07","current":3.916845,"twenty":6.239772,"median":8.777122,"eighty":13.248042,"marketCap":943607125},{"date":"2022-10-14","current":3.740679,"twenty":6.236636,"median":8.755886,"eighty":13.248042,"marketCap":901167051},{"date":"2022-10-21","current":4.087328,"twenty":6.230622,"median":8.734756,"eighty":13.241384,"marketCap":984678164},{"date":"2022-10-28","current":4.250707,"twenty":6.22179,"median":8.716798,"eighty":13.234727,"marketCap":1024037910},{"date":"2022-11-04","current":3.449288,"twenty":6.213362,"median":8.68891,"eighty":13.208098,"marketCap":1095762902},{"date":"2022-11-11","current":3.301892,"twenty":6.203808,"median":8.669307,"eighty":13.201441,"marketCap":1048938349},{"date":"2022-11-18","current":3.311575,"twenty":6.185826,"median":8.649704,"eighty":13.194783,"marketCap":1052014414},{"date":"2022-11-25","current":3.399797,"twenty":6.17312,"median":8.639313,"eighty":13.17348,"marketCap":1080040789},{"date":"2022-12-02","current":3.385811,"twenty":6.167844,"median":8.62969,"eighty":13.162828,"marketCap":1075597583},{"date":"2022-12-09","current":3.518145,"twenty":6.167844,"median":8.601399,"eighty":13.156171,"marketCap":1117637146},{"date":"2022-12-16","current":3.574091,"twenty":6.149862,"median":8.577106,"eighty":13.154839,"marketCap":1135409969},{"date":"2022-12-23","current":3.865656,"twenty":6.146266,"median":8.549709,"eighty":13.144188,"marketCap":1228033720},{"date":"2022-12-30","current":3.740853,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1188386653},{"date":"2023-01-06","current":3.441757,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1093370406},{"date":"2023-01-13","current":3.612823,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1147714231},{"date":"2023-01-20","current":3.620354,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1150106726},{"date":"2023-01-27","current":3.857048,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1225299440},{"date":"2023-02-03","current":4.130323,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1312112845},{"date":"2023-02-10","current":3.93774,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1250933319},{"date":"2023-02-17","current":3.875339,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1231109786},{"date":"2023-02-24","current":3.718259,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1181209167},{"date":"2023-03-03","current":3.363192,"twenty":6.130032,"median":8.492883,"eighty":13.133536,"marketCap":1194165378},{"date":"2023-03-10","current":3.211151,"twenty":6.113691,"median":8.482899,"eighty":13.133536,"marketCap":1140180220},{"date":"2023-03-17","current":2.830086,"twenty":6.097582,"median":8.463126,"eighty":13.133536,"marketCap":1004875645},{"date":"2023-03-24","current":2.875313,"twenty":6.070129,"median":8.365465,"eighty":13.133536,"marketCap":1020934521},{"date":"2023-03-31","current":2.985014,"twenty":6.034422,"median":8.291955,"eighty":13.130873,"marketCap":1059885838},{"date":"2023-04-06","current":2.892634,"twenty":6.016569,"median":8.274802,"eighty":13.130873,"marketCap":1027084729},{"date":"2023-04-14","current":2.896483,"twenty":5.960153,"median":8.185229,"eighty":13.133536,"marketCap":1028451442},{"date":"2023-04-20","current":2.925352,"twenty":5.879004,"median":8.105729,"eighty":13.133536,"marketCap":1038701788},{"date":"2023-04-28","current":2.932088,"twenty":5.726233,"median":7.998046,"eighty":13.136199,"marketCap":1041093536},{"date":"2023-05-05","current":2.771386,"twenty":5.536171,"median":7.943558,"eighty":13.136199,"marketCap":984033273},{"date":"2023-05-12","current":2.975648,"twenty":5.442294,"median":7.932539,"eighty":13.136199,"marketCap":1050433502},{"date":"2023-05-19","current":3.089052,"twenty":5.341054,"median":7.932539,"eighty":13.136199,"marketCap":1090466310},{"date":"2023-05-26","current":2.874844,"twenty":5.253436,"median":7.932539,"eighty":13.136199,"marketCap":1014848784},{"date":"2023-06-02","current":2.846736,"twenty":5.130475,"median":7.932539,"eighty":13.136199,"marketCap":1004926122},{"date":"2023-06-09","current":3.07839,"twenty":5.004569,"median":7.932539,"eighty":13.136199,"marketCap":1086702542},{"date":"2023-06-16","current":3.058036,"twenty":4.918423,"median":7.932539,"eighty":13.136199,"marketCap":1079517166},{"date":"2023-06-23","current":2.916523,"twenty":4.864674,"median":7.935774,"eighty":13.138862,"marketCap":1029561696},{"date":"2023-06-30","current":2.952386,"twenty":4.815342,"median":7.93772,"eighty":13.141525,"marketCap":1042221644},{"date":"2023-07-07","current":2.944631,"twenty":4.771165,"median":7.93772,"eighty":13.141525,"marketCap":1039484358},{"date":"2023-07-14","current":3.066759,"twenty":4.749076,"median":7.93772,"eighty":13.141525,"marketCap":1082596613},{"date":"2023-07-21","current":3.116192,"twenty":4.697536,"median":7.93772,"eighty":13.141525,"marketCap":1100046811},{"date":"2023-07-28","current":3.215057,"twenty":4.671766,"median":7.93772,"eighty":13.141525,"marketCap":1134947207},{"date":"2023-08-04","current":3.279998,"twenty":4.616544,"median":7.93772,"eighty":13.141525,"marketCap":1157871978},{"date":"2023-08-11","current":4.645552,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075069076},{"date":"2023-08-18","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-08-25","current":4.663295,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1079175005},{"date":"2023-09-01","current":4.624853,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1070278826},{"date":"2023-09-08","current":4.647031,"twenty":4.574583,"median":7.93772,"eighty":13.141525,"marketCap":1075411237},{"date":"2023-09-15","current":4.775663,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1105179222},{"date":"2023-09-22","current":4.867332,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1126393189},{"date":"2023-09-29","current":5.173389,"twenty":4.570147,"median":7.93772,"eighty":13.141525,"marketCap":1197220464},{"date":"2023-10-06","current":4.475521,"twenty":4.542915,"median":7.93772,"eighty":13.141525,"marketCap":1035720590},{"date":"2023-10-13","current":4.511006,"twenty":4.484012,"median":7.93772,"eighty":13.141525,"marketCap":1043932448},{"date":"2023-10-20","current":4.482914,"twenty":4.482914,"median":7.93772,"eighty":13.141525,"marketCap":1037431394},{"date":"2023-10-27","current":4.534662,"twenty":4.467537,"median":7.94745,"eighty":13.149513,"marketCap":1049407020},{"date":"2023-11-03","current":4.904296,"twenty":4.458666,"median":7.94745,"eighty":13.149513,"marketCap":1134947207},{"date":"2023-11-10","current":7.439549,"twenty":4.458666,"median":7.935774,"eighty":13.149513,"marketCap":1088071185},{"date":"2023-11-17","current":7.820894,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1143844827},{"date":"2023-11-24","current":7.993518,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1169092039},{"date":"2023-12-01","current":8.460278,"twenty":4.458666,"median":7.896854,"eighty":13.149513,"marketCap":1237357955},{"date":"2023-12-08","current":8.743603,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1278795691},{"date":"2023-12-15","current":8.690189,"twenty":4.459848,"median":7.902692,"eighty":13.146851,"marketCap":1270983658},{"date":"2023-12-22","current":9.616802,"twenty":4.459848,"median":7.934448,"eighty":13.146851,"marketCap":1406505433},{"date":"2023-12-29","current":9.686473,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1416695040},{"date":"2024-01-05","current":9.75382,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1426544994},{"date":"2024-01-12","current":9.809556,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1434696679},{"date":"2024-01-19","current":10.16023,"twenty":4.448612,"median":7.939666,"eighty":13.154839,"marketCap":1485984368},{"date":"2024-01-26","current":10.740814,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1570897761},{"date":"2024-02-02","current":10.601474,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1550518547},{"date":"2024-02-09","current":10.963759,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1603504503},{"date":"2024-02-16","current":11.124,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1626940600},{"date":"2024-02-23","current":10.647921,"twenty":4.452456,"median":7.93987,"eighty":13.154839,"marketCap":1557311618},{"date":"2024-03-01","current":11.10678,"twenty":4.4563,"median":7.940074,"eighty":13.154839,"marketCap":1583804596},{"date":"2024-03-08","current":11.32675,"twenty":4.4563,"median":7.94745,"eighty":13.154839,"marketCap":1615171958},{"date":"2024-03-15","current":10.799262,"twenty":4.4563,"median":7.990262,"eighty":13.154839,"marketCap":1539953125},{"date":"2024-03-22","current":11.659401,"twenty":4.4563,"median":8.049544,"eighty":13.154839,"marketCap":1662607257},{"date":"2024-03-28","current":10.571159,"twenty":4.4563,"median":8.239503,"eighty":13.154839,"marketCap":1507426062},{"date":"2024-04-05","current":10.811142,"twenty":4.452456,"median":8.461702,"eighty":13.154839,"marketCap":1541647243},{"date":"2024-04-12","current":11.186562,"twenty":4.452456,"median":8.566313,"eighty":13.154839,"marketCap":1595181367},{"date":"2024-04-19","current":10.81827,"twenty":4.452456,"median":8.624771,"eighty":13.154839,"marketCap":1542663714},{"date":"2024-04-26","current":11.245964,"twenty":4.4563,"median":8.639313,"eighty":13.154839,"marketCap":1603651956},{"date":"2024-05-03","current":11.324374,"twenty":4.4563,"median":8.690189,"eighty":13.154839,"marketCap":1614833134},{"date":"2024-05-10","current":14.682959,"twenty":4.4563,"median":8.734756,"eighty":13.168154,"marketCap":1565364893},{"date":"2024-05-17","current":13.78037,"twenty":4.4563,"median":8.734756,"eighty":13.224197,"marketCap":1469138999},{"date":"2024-05-24","current":14.166489,"twenty":4.4563,"median":8.734756,"eighty":13.241384,"marketCap":1510303519},{"date":"2024-05-31","current":15.403069,"twenty":4.4563,"median":8.734756,"eighty":13.248042,"marketCap":1642136538},{"date":"2024-06-07","current":15.399881,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1641796762},{"date":"2024-06-14","current":15.042931,"twenty":4.4563,"median":8.734756,"eighty":13.254699,"marketCap":1603741870},{"date":"2024-06-21","current":14.389583,"twenty":4.452456,"median":8.72747,"eighty":13.257384,"marketCap":1534087827},{"date":"2024-06-28","current":14.542562,"twenty":4.452456,"median":8.72747,"eighty":13.270766,"marketCap":1550397066},{"date":"2024-07-05","current":14.395957,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1534767378},{"date":"2024-07-12","current":13.586443,"twenty":4.452456,"median":8.72747,"eighty":13.285322,"marketCap":1448464320},{"date":"2024-07-19","current":12.767369,"twenty":4.452456,"median":8.72747,"eighty":13.228966,"marketCap":1361141934},{"date":"2024-07-26","current":12.910786,"twenty":4.452456,"median":8.72747,"eighty":13.052045,"marketCap":1376431846},{"date":"2024-08-02","current":13.302795,"twenty":4.452456,"median":8.72747,"eighty":12.924809,"marketCap":1418224272},{"date":"2024-08-09","current":12.449802,"twenty":4.452456,"median":8.72747,"eighty":12.75462,"marketCap":1335540014},{"date":"2024-08-16","current":13.196601,"twenty":4.452456,"median":8.72747,"eighty":12.789678,"marketCap":1415652134},{"date":"2024-08-23","current":13.473893,"twenty":4.452456,"median":8.72747,"eighty":13.02799,"marketCap":1445398406},{"date":"2024-08-30","current":14.204937,"twenty":4.452456,"median":8.72747,"eighty":13.191559,"marketCap":1523820396},{"date":"2024-09-06","current":13.316341,"twenty":4.452456,"median":8.72747,"eighty":13.222287,"marketCap":1428497115},{"date":"2024-09-13","current":13.558971,"twenty":4.452456,"median":8.72747,"eighty":13.305504,"marketCap":1454525103},{"date":"2024-09-20","current":14.226994,"twenty":4.452456,"median":8.72747,"eighty":13.395117,"marketCap":1526186577},{"date":"2024-09-27","current":14.085197,"twenty":4.452456,"median":8.72747,"eighty":13.544476,"marketCap":1510975415},{"date":"2024-10-04","current":14.976944,"twenty":4.452456,"median":8.72747,"eighty":13.679972,"marketCap":1606636722},{"date":"2024-10-11","current":14.803637,"twenty":4.452456,"median":8.72747,"eighty":13.85562,"marketCap":1588045302},{"date":"2024-10-18","current":14.529495,"twenty":4.452456,"median":8.72747,"eighty":14.019655,"marketCap":1558637056},{"date":"2024-10-25","current":14.772126,"twenty":4.452456,"median":8.72747,"eighty":14.168401,"marketCap":1584665044},{"date":"2024-11-01","current":14.778428,"twenty":4.452456,"median":8.72747,"eighty":14.27768,"marketCap":1585341095},{"date":"2024-11-08","current":13.141823,"twenty":4.452456,"median":8.73918,"eighty":14.377354,"marketCap":1640493731},{"date":"2024-11-15","current":13.379586,"twenty":4.452456,"median":8.78252,"eighty":14.377354,"marketCap":1670173717},{"date":"2024-11-22","current":14.322533,"twenty":4.452456,"median":8.81344,"eighty":14.377354,"marketCap":1787881840},{"date":"2024-11-29","current":15.251971,"twenty":4.452456,"median":8.883858,"eighty":14.399781,"marketCap":1903903601},{"date":"2024-12-06","current":15.273586,"twenty":4.452456,"median":8.934183,"eighty":14.482822,"marketCap":1906601781},{"date":"2024-12-13","current":14.4198,"twenty":4.452456,"median":9.012663,"eighty":14.537463,"marketCap":1800023652},{"date":"2024-12-20","current":12.93378,"twenty":4.452456,"median":9.090449,"eighty":14.537463,"marketCap":1614523744},{"date":"2024-12-27","current":12.995923,"twenty":4.452456,"median":9.19602,"eighty":14.537463,"marketCap":1622281013},{"date":"2025-01-03","current":12.766265,"twenty":4.452456,"median":9.268408,"eighty":14.537463,"marketCap":1593612846},{"date":"2025-01-10","current":12.631172,"twenty":4.448612,"median":9.31881,"eighty":14.538738,"marketCap":1576749218},{"date":"2025-01-17","current":14.282006,"twenty":4.448612,"median":9.382279,"eighty":14.538738,"marketCap":1782822752},{"date":"2025-01-24","current":13.892938,"twenty":4.448612,"median":9.455255,"eighty":14.538738,"marketCap":1734255503},{"date":"2025-01-31","current":14.63865,"twenty":4.448612,"median":9.481129,"eighty":14.558635,"marketCap":1827342730},{"date":"2025-02-07","current":15.684268,"twenty":4.448612,"median":9.514397,"eighty":14.63454,"marketCap":1957867210},{"date":"2025-02-14","current":15.462716,"twenty":4.448612,"median":9.568033,"eighty":14.675959,"marketCap":1930210860},{"date":"2025-02-21","current":15.732902,"twenty":4.448612,"median":9.580931,"eighty":14.694621,"marketCap":1963938116},{"date":"2025-02-28","current":20.937616,"twenty":4.448612,"median":9.626092,"eighty":14.774647,"marketCap":1933567942},{"date":"2025-03-07","current":19.49754,"twenty":4.444767,"median":9.675026,"eighty":14.838928,"marketCap":1800578330},{"date":"2025-03-14","current":19.960552,"twenty":4.444767,"median":9.675026,"eighty":14.901539,"marketCap":1843337016},{"date":"2025-03-21","current":19.362647,"twenty":4.444767,"median":9.689317,"eighty":15.017908,"marketCap":1788121076},{"date":"2025-03-28","current":19.698057,"twenty":4.444767,"median":9.708699,"eighty":15.110765,"marketCap":1819095871},{"date":"2025-04-04","current":17.87153,"twenty":4.444767,"median":9.75606,"eighty":15.125044,"marketCap":1650417909},{"date":"2025-04-11","current":17.576223,"twenty":4.448612,"median":9.799015,"eighty":15.243459,"marketCap":1623146621},{"date":"2025-04-17","current":18.509538,"twenty":4.448612,"median":9.802712,"eighty":15.283315,"marketCap":1709337357},{"date":"2025-04-25","current":18.910572,"twenty":4.444767,"median":9.80686,"eighty":15.360398,"marketCap":1746372438},{"date":"2025-05-02","current":18.710055,"twenty":4.444767,"median":9.80686,"eighty":15.401794,"marketCap":1727854897},{"date":"2025-05-09","current":14.05872,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1621799891},{"date":"2025-05-16","current":14.406029,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1661865116},{"date":"2025-05-23","current":14.373925,"twenty":4.444767,"median":9.80686,"eighty":15.43196,"marketCap":1658161608},{"date":"2025-05-30","current":15.450609,"twenty":4.444767,"median":9.80686,"eighty":15.444645,"marketCap":1782366767},{"date":"2025-06-06","current":15.621074,"twenty":4.444767,"median":9.80686,"eighty":15.514776,"marketCap":1802031456},{"date":"2025-06-13","current":16.520424,"twenty":4.444767,"median":9.80686,"eighty":15.572999,"marketCap":1905779645},{"date":"2025-06-20","current":16.170677,"twenty":4.440923,"median":9.804164,"eighty":15.627805,"marketCap":1865433127},{"date":"2025-06-27","current":15.57111,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1796267668},{"date":"2025-07-03","current":15.479999,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1785757230},{"date":"2025-07-11","current":15.432974,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1780332488},{"date":"2025-07-18","current":14.992116,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1729475533},{"date":"2025-07-25","current":15.333047,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1768804912},{"date":"2025-08-01","current":15.430035,"twenty":4.440923,"median":9.804164,"eighty":15.665123,"marketCap":1779993442},{"date":"2025-08-08","current":17.700627,"twenty":4.440923,"median":9.82349,"eighty":15.67238,"marketCap":1703526003},{"date":"2025-08-15","current":17.97186,"twenty":4.440923,"median":9.917298,"eighty":15.726991,"marketCap":1729629785},{"date":"2025-08-22","current":17.975383,"twenty":4.440923,"median":9.97212,"eighty":15.765277,"marketCap":1729968795},{"date":"2025-08-29","current":18.669318,"twenty":4.440923,"median":10.032501,"eighty":15.848057,"marketCap":1796753795},{"date":"2025-09-05","current":18.391039,"twenty":4.437079,"median":10.161405,"eighty":15.873833,"marketCap":1769971993},{"date":"2025-09-12","current":18.229004,"twenty":4.440923,"median":10.244717,"eighty":15.951577,"marketCap":1754377526},{"date":"2025-09-19","current":17.911977,"twenty":4.440923,"median":10.348339,"eighty":16.07924,"marketCap":1723866612},{"date":"2025-09-26","current":17.668924,"twenty":4.440923,"median":10.483035,"eighty":16.238322,"marketCap":1700474912},{"date":"2025-10-03","current":16.622738,"twenty":4.440923,"median":10.565798,"eighty":16.310589,"marketCap":1599788897},{"date":"2025-10-10","current":15.678704,"twenty":4.440923,"median":10.601474,"eighty":16.329708,"marketCap":1508934177},{"date":"2025-10-17","current":15.460308,"twenty":4.440923,"median":10.638631,"eighty":16.329708,"marketCap":1487915548},{"date":"2025-10-24","current":16.192991,"twenty":4.440923,"median":10.724558,"eighty":16.329708,"marketCap":1558429659},{"date":"2025-10-31","current":15.978118,"twenty":4.440923,"median":10.745006,"eighty":16.329708,"marketCap":1537750040},{"date":"2025-11-07","current":15.678704,"twenty":4.440923,"median":10.777877,"eighty":16.329708,"marketCap":1508934177},{"date":"2025-11-14","current":18.215203,"twenty":4.440923,"median":10.808766,"eighty":16.403793,"marketCap":1432862540},{"date":"2025-11-21","current":18.438808,"twenty":4.440923,"median":10.856288,"eighty":16.560326,"marketCap":1450451976},{"date":"2025-11-28","current":18.911819,"twenty":4.440923,"median":10.868211,"eighty":16.63112,"marketCap":1487660399},{"date":"2025-12-05","current":19.647135,"twenty":4.440923,"median":10.912667,"eighty":16.757487,"marketCap":1545502583},{"date":"2025-12-12","current":19.023621,"twenty":4.440923,"median":10.960835,"eighty":17.137473,"marketCap":1496455117},{"date":"2025-12-19","current":18.228104,"twenty":4.440923,"median":11.01485,"eighty":17.334253,"marketCap":1433877315},{"date":"2025-12-26","current":18.425908,"twenty":4.440923,"median":11.091519,"eighty":17.554114,"marketCap":1449437201},{"date":"2026-01-02","current":17.995898,"twenty":4.440923,"median":11.134288,"eighty":17.640744,"marketCap":1415611362},{"date":"2026-01-09","current":18.017399,"twenty":4.440923,"median":11.163158,"eighty":17.676428,"marketCap":1417302654}],"updateTime":1768161730400},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GLP\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2591898820","title":"China's GLP-1 Weight-Loss Market Faces Rising Price Competition -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2591898820","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591898820?lang=en_us&edition=fundamental","pubTime":"2025-12-16 18:00","pubTimestamp":1765879200,"startTime":"0","endTime":"0","summary":"1000 GMT - Pricing competition in China's GLP-1 weight-loss drug market is expected to heat up, HSBC analysts say in a note. The inclusion of Eli Lilly's tirzepatide treatment in China's national reimbursement drug list was a surprise to the market and raises concerns about the sales outlook of Innovent's mazdutide drug, they say. A price cut for GLP-1 drugs will quickly raise market penetration as the treatments only received approval in China in 2025. However, given there are multiple domestic GLP-1 treatments in the pipeline, a more aggressive pricing strategy may hurt sales for all drugmakers, they add. HSBC awaits more updates from China's oral GLP-1 developers, including Ascletis and Hengrui. The bank maintains a buy call on Innovent and hold ratings on Livzon and Fosun Pharma. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4590","LU0310800965.SGD","LU0128525689.USD","LU1267930227.SGD","GLP","BK4207","BK4521","LU0052756011.USD","BK4585","BK4144","HSBC","LU2236285917.USD"],"gpt_icon":0},{"id":"2591627198","title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2591627198","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591627198?lang=en_us&edition=fundamental","pubTime":"2025-12-16 06:37","pubTimestamp":1765838259,"startTime":"0","endTime":"0","summary":"Global GP LLC has reported the acquisition of common shares of Global Partners LP, according to a recent Form 4 filing with the SEC. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Partners LP published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 15, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL6wLWjG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","BK4590","GLP"],"gpt_icon":0},{"id":"2591262804","title":"Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2591262804","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591262804?lang=en_us&edition=fundamental","pubTime":"2025-12-16 00:35","pubTimestamp":1765816526,"startTime":"0","endTime":"0","summary":"Eli Lilly's  GLP-1 franchise for weight loss is set to drive 26% revenue growth in 2026, BofA Securities said in a Monday note.The company expects to launch orfoglipron in Q2 2026 and could lead to a \"meaningful\" category expansion, the investment firm said. Orfoglipron should launch well and could generate $3 billion in revenue in the first year, BofA noted.Meanwhile, Mounjaro is expected to remain Eli Lilly's \"top selling brand for the foreseeable future,\" for diabetes in the US and for both obesity and diabetes outside the US, the investment firm said.In addition, Eli Lilly's recent US government deal is expected to spur uptake of the company's obesity medications starting in Q2 2026, BofA said.BofA lowered its price target on Eli Lilly to $1,268 from $1,286, while maintaining its buy rating.Price: 1059.05, Change: +31.54, Percent Change: +3.07","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LLY","GLP"],"gpt_icon":1},{"id":"1148356245","title":"BESUNYEN (00926) Increases Investment in ERX to Maintain 3% Stake, Backing Non-GLP-1 Obesity Therapy Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=1148356245","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148356245?lang=en_us&edition=fundamental","pubTime":"2025-12-12 17:30","pubTimestamp":1765531831,"startTime":"0","endTime":"0","summary":"BESUNYEN (00926) announced that the company expects to record a significant fair value loss of approximately RMB 16.3 million on its investment in ERX Pharmaceuticals Inc., a clinical-stage...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4590","ERX","BK4144","00926","GLP","BK1237"],"gpt_icon":0},{"id":"1132274427","title":"Youcare Pharmaceutical's Song Gengshen Warns: GLP-1 Weight Loss Drugs May Cause Depression, Dubbed \"Emotion-Numbing Medication\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1132274427","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132274427?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:33","pubTimestamp":1765420388,"startTime":"0","endTime":"0","summary":"The \"2025 China Enterprise Competitiveness Annual Conference\" was held in Beijing from December 9 to 10. Song Gengshen, Director of the Drug Research Institute and Board Member of Youcare...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","GLP","BK0239","BK4590","688658"],"gpt_icon":0},{"id":"2590534265","title":"FTC Release: FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2590534265","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590534265?lang=en_us&edition=fundamental","pubTime":"2025-12-11 02:05","pubTimestamp":1765389900,"startTime":"0","endTime":"0","summary":"The Federal Trade Commission has given final approval to an order against telemedicine company NextMed and its principals, requiring them to stop deceptively advertising weight-loss programs and to stop using deceptive and unfair billing and cancellation practices.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","FTC","BK4144","BK4590"],"gpt_icon":0},{"id":"2590632404","title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2590632404","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590632404?lang=en_us&edition=fundamental","pubTime":"2025-12-10 05:51","pubTimestamp":1765317090,"startTime":"0","endTime":"0","summary":"Global GP LLC has reported the acquisition of common shares of Global Partners LP, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Partners LP published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL8GTJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","BK4590","GLP"],"gpt_icon":0},{"id":"2589336294","title":"Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted Weight Loss of 7.7% with Better Gastrointestinal Tolerability in Its 13-Week U.S. Phase II Study in Participants with Obesity or Overweight","url":"https://stock-news.laohu8.com/highlight/detail?id=2589336294","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589336294?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:40","pubTimestamp":1765186800,"startTime":"0","endTime":"0","summary":"- ASC30 once-daily tablets showed statistically significant and clinically meaningful dose-dependent placebo-adjusted mean body weight reductions with no observed plateau for weight loss.- ASC30 titrated weekly to target dose demonstrated approximately one-half the rate of vomiting observed with orforglipron titrated weekly.- No hepatic safety signal was observed, and no elevations of alanine transaminase , aspartate aminotransferase  or total bilirubin  were observed.At the 13-week primary endpoint, ASC30 once-daily tablets showed dose-dependent placebo-adjusted mean body weight reductions of 5.4%, 7.0% and 7.7% for 20mg, 40 mg and 60 mg, respectively.No plateau was observed for weight loss. The baseline mean body weight and body mass index of participants were 107.3kg and 38.6 kg/m2, respectively.The vomiting rate of ASC30 titrated weekly to target dose wasapproximately half of the published vomiting rate observed with orforglipron titrated weekly . The gastrointestinal tolerability ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-oral-small-molecule-glp-1--asc30--demonstrated-placebo-adjusted-weight-loss-of-7-7-with-better-gastrointestinal-tolerability-in-its-13-week-us-phase-ii-study-in-participants-with-obesity-or-overweight-302635184.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP"],"gpt_icon":0},{"id":"2589801875","title":"Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589801875","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589801875?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:20","pubTimestamp":1765149600,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Dec.  07, 2025  (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for m","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201156/0/en/Structure-Therapeutics-to-Report-Data-from-ACCESS-Clinical-Program-of-Oral-Small-Molecule-GLP-1-Receptor-Agonist-Aleniglipron-on-December-8-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4539","GLP","BK4590","BK4144","BK4139","GPCR","LENZ","BK4007"],"gpt_icon":0},{"id":"1184800620","title":"CSPC PHARMA (01093): GLP-1/GIP Receptor Dual-Targeting Agonist Polypeptide Injection Approved for Clinical Trials in the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=1184800620","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184800620?lang=en_us&edition=fundamental","pubTime":"2025-12-05 19:00","pubTimestamp":1764932435,"startTime":"0","endTime":"0","summary":"CSPC PHARMA (01093) announced that its GLP-1/GIP receptor dual-targeting agonist polypeptide injection (SYH2069 injection) has received approval from the U.S. Food and Drug Administration (FDA) to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","IE00BZ08YR35.GBP","BK4144","LU1813983027.USD","IE00BZ08YT58.USD","LU1951186391.HKD","BK1515","IE00B031HY20.USD","LU1226288170.HKD","LU1226287529.USD","LU0326950275.SGD","LU0314109678.HKD","LU1960683339.HKD","BK1191","HK0000165453.HKD","SG9999004220.SGD","LU1226288253.USD","LU2039709279.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","01093","LU0140636845.USD","LU0880133367.SGD","LU1226287792.SGD","LU0072913022.USD","IE00B543WZ88.USD","LU1008478684.HKD","LU0315179316.USD","BK1521","LU0501845795.SGD","LU1152091754.HKD","GLP","LU1152091168.USD","LU1807302812.USD","LU1226287875.USD","LU1328277881.USD","LU0067412154.USD","IE0008368742.USD","BK4590"],"gpt_icon":0},{"id":"2589822818","title":"Lepu Biopharma (SEHK:2157): Valuation Check After New GLP-1 CDMO Framework Deal With Lepu Medical","url":"https://stock-news.laohu8.com/highlight/detail?id=2589822818","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589822818?lang=en_us&edition=fundamental","pubTime":"2025-12-05 16:31","pubTimestamp":1764923516,"startTime":"0","endTime":"0","summary":"Lepu Biopharma (SEHK:2157) just signed a GLP-1 focused CDMO framework deal with related party Lepu Medical, a move that could turn spare manufacturing capacity into recurring cashflow and reshape how investors think about its pipeline driven story.\nSee our latest analysis for Lepu Biopharma.\nThe 1 day share price return of 3.0% to HK$5.76 comes after a volatile few months, with the 3 month share price return still down sharply. However, the year to date share price return and 1 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-valuation-check-after-new-glp-1-cdmo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-valuation-check-after-new-glp-1-cdmo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK4139","02157","BK4590","BK4144","GLP","CDMO"],"gpt_icon":0},{"id":"2589724830","title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2589724830","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589724830?lang=en_us&edition=fundamental","pubTime":"2025-12-05 06:01","pubTimestamp":1764885668,"startTime":"0","endTime":"0","summary":"Global GP LLC has reported the acquisition of common shares of Global Partners LP, according to a recent regulatory filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Partners LP published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL85k2Dv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4144","BK4590"],"gpt_icon":0},{"id":"1175527700","title":"SINO BIOPHARM (01177) Receives NMPA and FDA Approval for Clinical Trial of TQF3250, an \"Oral Biased GLP-1 Receptor Agonist\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1175527700","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175527700?lang=en_us&edition=fundamental","pubTime":"2025-12-04 17:30","pubTimestamp":1764840619,"startTime":"0","endTime":"0","summary":"SINO BIOPHARM (01177) announced that its self-developed innovative drug, TQF3250 capsules—an \"oral biased GLP-1 receptor agonist\"—has received clinical trial approval from China's National Medical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ08YS42.EUR","BK1589","BK1521","GLP","01177","BK1191","BK4590","BK1515","IE00BZ08YT58.USD","HK0000165453.HKD","IE00BZ08YR35.GBP","BK4144"],"gpt_icon":0},{"id":"2588202590","title":"FTC Release: FTC Approves Final Order against Telehealth Provider NextMed Over Charges It Used Deceptive Advertising Claims to Sell GLP-1 Weight-Loss Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2588202590","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588202590?lang=en_us&edition=fundamental","pubTime":"2025-12-04 02:04","pubTimestamp":1764785040,"startTime":"0","endTime":"0","summary":"The Federal Trade Commission has given final approval to an order against telemedicine company NextMed and its principals, requiring them to stop deceptively advertising weight-loss programs and to stop using deceptive and unfair billing and cancellation practices.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4144","GLP","FTC","BK4590"],"gpt_icon":0},{"id":"2588044239","title":"Burger King Primed for GLP-1 Shift -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2588044239","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588044239?lang=en_us&edition=fundamental","pubTime":"2025-12-03 22:15","pubTimestamp":1764771300,"startTime":"0","endTime":"0","summary":"0914 ET - Restaurant executives are watching for signs of slower sales as more Americans take GLP-1 weight loss drugs, but Burger King owner Restaurant Brands International thinks it's prepared to meet any demand shift. Weight-loss drug users often seek out protein while using the medications, and Burger King's products are protein rich, CEO Josh Kobza said during an investor event. The chain's Double Cheeseburger is a smaller size with a high meat to bread ratio, making it a potential draw for GLP-1 users, Kobza says. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4209","BK4144","QSR","BK4590"],"gpt_icon":0},{"id":"2588705880","title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588705880","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588705880?lang=en_us&edition=fundamental","pubTime":"2025-12-02 05:38","pubTimestamp":1764625114,"startTime":"0","endTime":"0","summary":"Global GP LLC has reported the acquisition of common shares of Global Partners LP, according to a recent regulatory filing. The filing lists Global GP LLC as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Global Partners LP published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 01, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDLc1CWwF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Global GP LLC Reports Acquisition of Global Partners LP Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK4144","BK4590"],"gpt_icon":0},{"id":"2588772817","title":"Are GLP-1s The New Performance-Enhancing Drug For Careers?","url":"https://stock-news.laohu8.com/highlight/detail?id=2588772817","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588772817?lang=en_us&edition=fundamental","pubTime":"2025-12-02 01:01","pubTimestamp":1764608460,"startTime":"0","endTime":"0","summary":"Some professions — think tenured professor or Supreme Court justice — are largely insulated from the pressure to maintain a specific look. The same cannot be said in the high-stakes arenas of finance, real estate and design, where the quest for a competitive edge has well-established self-maintenance rituals: coloring gray hairs, meticulously curated wardrobe and submitting oneself to Botox needles.Now, that pursuit has evolved to include another new, potent class of injectable: glucagon-like peptide-1 drugs like Ozempic, Wegovy and Zepbound.While approved for diabetes and obesity, the medications are being adopted off-label by a growing cadre of professionals who see them not just as a path to better health, but as a direct investment in their career trajectory. The driving force is an open secret in many industries — being trim confers a professional and financial advantage.See Also: Forget Flipping Houses—This Fund Lets You Invest in Home Equity Like Wall Street","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/01/Ozempic--Mounjaro-Users-Cut-6-5-Billion-.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/01/Ozempic--Mounjaro-Users-Cut-6-5-Billion-.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/topics/25/12/49141491/are-glp-1s-the-new-performance-enhancing-drug-for-careers","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/topics/25/12/49141491/are-glp-1s-the-new-performance-enhancing-drug-for-careers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["LU2265009873.SGD","LU2471134879.HKD","SGXZ99366536.SGD","LU2750360997.AUD","BK4581","LU0109391861.USD","LU0708995401.HKD","LU1623119135.USD","SG9999014898.SGD","LU0289739699.SGD","LU2112291526.USD","IE00BJLML261.HKD","BK4588","LU0456855351.SGD","LU0320765992.SGD","BK4599","LU1057294990.SGD","LU2237443895.HKD","GB00BDT5M118.USD","IE0009355771.USD","LU0320765059.SGD","LU2211815571.USD","LU0882574055.USD","LU2168563687.JPY","LU1988902786.USD","LU2602419157.SGD","LLY","LU2237443465.HKD","LU2237443622.USD","GLP","SG9999015978.USD","IE00BWXC8680.SGD","LU2361045086.USD","LU1023059063.AUD","LU2746668461.USD","LU0198837287.USD","LU1551013342.USD","LU1868837136.USD","LU0266013472.USD","LU1323610961.USD","NVO","LU1917777945.USD","LU1804176565.USD","LU2108987350.USD","LU1548497426.USD","LU0354030511.USD","LU0058720904.USD","IE00BK4W5L77.USD","SGXZ31699556.SGD","LU1093756168.USD"],"gpt_icon":1},{"id":"1187203221","title":"ASCLETIS-B (01672) Selects Its First Oral GLP-1R/GIPR/GCGR Triple-Target Agonist Peptide ASC37 for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=1187203221","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187203221?lang=en_us&edition=fundamental","pubTime":"2025-11-30 18:40","pubTimestamp":1764499221,"startTime":"0","endTime":"0","summary":"ASCLETIS-B (01672) announced that it has selected its first oral GLP-1R/GIPR/GCGR triple-target agonist peptide, ASC37 oral tablets, as a clinical development candidate. The company plans to submit...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLP","BK1191","BK1574","BK4590","01672","BK1161","GIPR","01477","BK1515","BK4144","BK4160"],"gpt_icon":0},{"id":"2587618791","title":"Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2587618791","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587618791?lang=en_us&edition=fundamental","pubTime":"2025-11-30 18:15","pubTimestamp":1764497700,"startTime":"0","endTime":"0","summary":"- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology , ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to-head non-human primate  studies.- ASC37 oral tablets' drug exposure, as measured by the area under curve , was approximately 57-fold of retatrutide's drug exposure in head-to-head NHP studies.- Average observed half-life of ASC37 oral tablets was approximately 56 hours in NHP studies, supporting once daily and less frequent oral dosing.- ASC37 in vitro activity was approximately 5-, 4- and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC37 oral tablets is expected in the second quarter of 2026.\"Selection of ASC37, a promising oral GLP-1R/GIPR/GCGR triple peptide agonist,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-its-first-oral-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302628540.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND.AU","BK4590","BK4144","GIPR","IND","BK7095","BK4160","BK7104","GLP","AUC.AU"],"gpt_icon":0},{"id":"2586206014","title":"GLP J-REIT Signs Interest Rate Swap Agreements to Stabilize Borrowing Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2586206014","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586206014?lang=en_us&edition=fundamental","pubTime":"2025-11-28 14:58","pubTimestamp":1764313124,"startTime":"0","endTime":"0","summary":"The latest update is out from GLP J-REIT ( ($JP:3281) ). GLP J-REIT has signed interest rate swap agreements to manage the interest rates on its re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glp-j-reit-signs-interest-rate-swap-agreements-to-stabilize-borrowing-costs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glp-j-reit-signs-interest-rate-swap-agreements-to-stabilize-borrowing-costs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4144","GLP","REIT","BK4590"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":194,"code":"91000000","status":"200"}]}}